» Articles » PMID: 25621108

Identify Multiple Myeloma Stem Cells: Utopia?

Overview
Date 2015 Jan 27
PMID 25621108
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Multiple myeloma (MM) is a hematologic malignancy of monoclonal plasma cells which remains incurable despite recent advances in therapies. The presence of cancer stem cells (CSCs) has been demonstrated in many solid and hematologic tumors, so the idea of CSCs has been proposed for MM, even if MM CSCs have not been define yet. The existence of myeloma CSCs with clonotypic B and clonotypic non B cells was postulated by many groups. This review aims to focus on these distinct clonotypic subpopulations and on their ability to develop and sustain MM. The bone marrow microenvironment provides to MM CSCs self-renewal, survival and drug resistance thanks to the presence of normal and cancer stem cell niches. The niches and CSCs interact each other through adhesion molecules and the interplay between ligands and receptors activates stemness signaling (Hedgehog, Wnt and Notch pathways). MM CSCs are also supposed to be responsible for drug resistance that happens in three steps from the initial cancer cell homing microenvironment-mediated to development of microenvironment-independent drug resistance. In this review, we will underline all these aspects of MM CSCs.

Citing Articles

Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells.

Bhowmick K, von Suskil M, Al-Odat O, Elbezanti W, Jonnalagadda S, Budak-Alpdogan T Heliyon. 2024; 10(12):e33091.

PMID: 39021902 PMC: 11252793. DOI: 10.1016/j.heliyon.2024.e33091.


Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma.

Al-Odat O, Guirguis D, Schmalbach N, Yao G, Budak-Alpdogan T, Jonnalagadda S Int J Mol Sci. 2023; 24(1).

PMID: 36614089 PMC: 9820338. DOI: 10.3390/ijms24010644.


The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas".

Solimando A, Da Via M, Bolli N, Steinbrunn T Cancers (Basel). 2022; 14(13).

PMID: 35805041 PMC: 9265748. DOI: 10.3390/cancers14133271.


Multiple Myeloma: Available Therapies and Causes of Drug Resistance.

Pinto V, Bergantim R, Caires H, Seca H, Guimaraes J, Vasconcelos M Cancers (Basel). 2020; 12(2).

PMID: 32050631 PMC: 7072128. DOI: 10.3390/cancers12020407.


Multiple myeloma cancer stem cells.

Gao M, Kong Y, Yang G, Gao L, Shi J Oncotarget. 2016; 7(23):35466-77.

PMID: 27007154 PMC: 5085244. DOI: 10.18632/oncotarget.8154.


References
1.
Karadag A, Oyajobi B, Apperley J, Russell R, Croucher P . Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol. 2000; 108(2):383-90. DOI: 10.1046/j.1365-2141.2000.01845.x. View

2.
Lapidot T, Petit I . Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 2002; 30(9):973-81. DOI: 10.1016/s0301-472x(02)00883-4. View

3.
Kellner J, Liu B, Kang Y, Li Z . Fact or fiction--identifying the elusive multiple myeloma stem cell. J Hematol Oncol. 2013; 6:91. PMC: 4029203. DOI: 10.1186/1756-8722-6-91. View

4.
Nilsson S, Johnston H, Coverdale J . Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood. 2001; 97(8):2293-9. DOI: 10.1182/blood.v97.8.2293. View

5.
Taipale J, Beachy P . The Hedgehog and Wnt signalling pathways in cancer. Nature. 2001; 411(6835):349-54. DOI: 10.1038/35077219. View